ALK2 Inhibitor

M4K2281 is a selecitve inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 2 nM. M4K2281 exhibits a moderate blood brain permeability with a brain to plasma ratio of 3.7 at 4h.

ALK5-IN-33 (Compound EX-10) is a selective, orally active ALK-5 inhibitor with an IC₅₀ ≤10 nM.

RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a K_D of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation.

CDD-1115 is a BMPR2 serine/threonine kinase inhibitor with an IC₅₀ of 1.8 nM against human BMPR2 kinase. CDD-1115 selectively inhibits the catalytic activity of BMPR2, and shows weak inhibitory effects on ALK1 and ALK2.

ALK5-IN-25 (compound EX-02) is a potent ALK-5 inhibitor with an IC₅₀ ≤10 nM.ALK5-IN-25 also inhibits ALK-2 (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer.

M4K2308 is a selective ether-linked inhibitor of ALK2 with an IC₅₀ of 2 nM. M4K2308 exhibits exceptional selectivity for ALK2 over ALK5 (IC₅₀ of 224 nM). M4K2308 has the potential for the study of diffuse intrinsic pontine glioma (DIPG) research.

MU1700, a chemical probe, is an orally active and potent ALK1/2 inhibitor with IC₅₀s of 13 nM and 6 nM, respectively. MU1700 shows cell membrane permeability and high brain permeability.

ALK5-IN-27 (Compound EX-04) is a potent ALK-5 inhibitor with an IC₅₀ ≤10 nM. ALK5-IN-27 also inhibits ALK-2 (selectivity ALK2/ALK5 ≤10).

M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6.

ALK2-IN-6 (Compound 14a) is a selective ALK2 inhibitor, with an IC₅₀ of 9 nM. ALK2-IN-6 can be used in the research of diffuse intrinsic pontine glioma.

M4K2009 hydrochloride is an orally active, blood-brain barrier permeable type I ALK2 inhibitor, with an IC₅₀ value of 8-13 nM against human ALK2. M4K2009 hydrochloride exhibits moderate off-target inhibitory activity against hERG potassium channels (Potassium Channel), with an IC₅₀ of 8 μM against the human channel. M4K2009 hydrochloride can be used in studies related to diffuse intrinsic pontine glioma.